Jeff E. Knight - Jul 15, 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Operating Officer
Signature
Marc Wilson, as attorney-in-fact
Stock symbol
CRNX
Transactions as of
Jul 15, 2024
Transactions value $
-$895,884
Form type
4
Date filed
7/17/2024, 05:35 PM
Previous filing
Jun 28, 2024
Next filing
Nov 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $420K +17.5K +33.28% $23.98 70.1K Jul 15, 2024 Direct
transaction CRNX Common Stock Options Exercise $57.8K +2.89K +4.12% $20.02 73K Jul 15, 2024 Direct
transaction CRNX Common Stock Options Exercise $112K +5.69K +7.79% $19.64 78.7K Jul 15, 2024 Direct
transaction CRNX Common Stock Sale -$1.49M -27K -34.33% $55.00 51.7K Jul 15, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock option (Right to Buy) Options Exercise $0 -17.5K -13.46% $0.00 113K Jul 15, 2024 Common Stock 17.5K $23.98 Direct F2
transaction CRNX Stock option (Right to Buy) Options Exercise $0 -2.89K -12.5% $0.00 20.2K Jul 15, 2024 Common Stock 2.89K $20.02 Direct F3
transaction CRNX Stock option (Right to Buy) Options Exercise $0 -5.69K -6.25% $0.00 85.3K Jul 15, 2024 Common Stock 5.69K $19.64 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
F3 1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
F4 1/48th of the shares subject to the option vested on April 1, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.